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PDGFR	is	an	important	target	for	novel	anticancer	therapeutics	because	it	is	overexpressed	in	a	wide	variety	of	
malignancies.	Recently,	however,	several	anticancer	drugs	that	inhibit	PDGFR	signaling	have	been	associated	
with	clinical	heart	failure.	Understanding	this	effect	of	PDGFR	inhibitors	has	been	difficult	because	the	role	of	
PDGFR	signaling	in	the	heart	remains	largely	unexplored.	As	described	herein,	we	have	found	that	PDGFR-β	
expression	and	activation	increase	dramatically	in	the	hearts	of	mice	exposed	to	load-induced	cardiac	stress.	
In	mice	in	which	Pdgfrb	was	knocked	out	in	the	heart	in	development	or	in	adulthood,	exposure	to	load-
induced	stress	resulted	in	cardiac	dysfunction	and	heart	failure.	Mechanistically,	we	showed	that	cardiomyo-
cyte	PDGFR-β	signaling	plays	a	vital	role	in	stress-induced	cardiac	angiogenesis.	Specifically,	we	demonstrated	
that	cardiomyocyte	PDGFR-β	was	an	essential	upstream	regulator	of	the	stress-induced	paracrine	angiogenic	
capacity	(the	angiogenic	potential)	of	cardiomyocytes.	These	results	demonstrate	that	cardiomyocyte	PDGFR-β	
is	a	regulator	of	the	compensatory	cardiac	response	to	pressure	overload–induced	stress.	Furthermore,	our	
findings	may	provide	insights	into	the	mechanism	of	cardiotoxicity	due	to	anticancer	PDGFR	inhibitors.
Introduction
PDGF receptors and/or ligands are overexpressed in a wide vari-
ety of malignancies (1–4). In the past decade, a number of inhibi-
tors of receptor tyrosine kinases (RTKs) whose targets include 
PDGFR have emerged as agents with remarkable efficacy in the 
treatment of human cancers (5–7). However, several of these 
agents have been linked to the development of cardiomyopathy 
in subsets of treated patients.
Recent reports indicate that the anticancer agent sunitinib, 
whose targets include PDGFR, causes cardiac dysfunction in up 
to 19% of treated patients (8), and we and others have reported 
the development of clinical heart failure in subsets of sunitinib-
treated patients (8–10). Sorafenib, another RTK inhibitor that 
targets PDGFR, was recently associated with myocardial damage 
and cardiac dysfunction in renal cell carcinoma patients (10). In 
addition, imatinib, whose targets include PDGFR in addition to 
Abl kinase, has been linked to the development of cardiomyopathy 
(11), although this appears to be an infrequent clinical occurrence 
(12). Importantly, both sunitinib and sorafenib lead to the devel-
opment of subacute, severe hypertension in substantial numbers 
of patients (8, 13), while imatinib rarely causes hypertension.
Linking the incidence of cardiomyopathy associated with anti-
cancer PDGFR inhibitors with the relative incidences of hyper-
tension associated with these drugs led us to hypothesize that 
PDGFR signaling in the heart may play a key role in the cardiac 
response to vascular stress such as hypertension. However, little 
is known regarding the role of PDGFR signaling in adult cardio-
myocytes. We show here that cardiomyocyte PDGFR-β expres-
sion and activation rise dramatically in response to pressure 
overload–induced stress. Furthermore, we show that knockout 
of PDGFR-β in the cardiomyocyte results in cardiac dysfunc-
tion, heart failure, and a marked defect in stress-induced cardiac 
angiogenesis. Mechanistically, we demonstrate that PDGFR-β 
is an essential regulator of the paracrine angiogenic capacity, or 
angiogenic potential, of cardiomyocytes.
Results
PDGFR-β expression in cardiomyocytes increases dramatically in response 
to pressure overload–induced stress. We exposed C57BL/6 mice to 
transverse aortic constriction (TAC), in which a ligature is placed 
at the aortic arch, resulting in acute pressure overload. As expected, 
we observed profound increases in cardiac weight (Figure 1A) 
and cardiac thickness (Figure 1B) in mice exposed to TAC. Car-
diac lysates from mice exposed to TAC exhibited increased levels 
of PDGFR-β persisting to 14 days after TAC (Figure 1C). Quanti-
tative densitometry revealed a 10-fold increase in PDGFR-β pro-
tein levels in the heart 7 days after TAC (Figure 1D). Enhanced 
PDGFR-β expression after TAC was predominantly seen on car-
diomyocytes (Figure 1E), as opposed to non-myocyte cells within 
the heart such as fibroblasts or endothelial cells. A substantial 
increase in phosphorylated, activated PDGFR-β was seen in the 
heart 7 days after TAC (Figure 1F) and 14 days after TAC (data 
not shown), suggesting that changes in PDGFR-β in the cardio-
myocyte after TAC were functionally important. Marked increases 
in levels of phosphorylated Akt and ERK1/2, established down-
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stream effectors of PDGFR-β, were also observed in the heart after 
TAC. Immunohistochemistry with a phospho-specific PDGFR-β 
antibody demonstrated that phospho–PDGFR-β after TAC was 
increased predominantly in cardiomyocytes (Figure 1G). Levels of 
PDGFR-α were increased in the hearts of mice exposed to TAC 
compared with sham-operated mice (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI39434DS1), but we observed no increase in phosphorylation of 
PDGFR-α (data not shown), suggesting a dominant biological role 
of PDGFR-β compared with PDGFR-α in the heart after exposure 
to load stress. We also observed significantly increased levels of 
local expression of the PDGFR-β ligands PDGF-B and PDGF-C 
3 days after TAC (Supplemental Figure 2), while levels of PDGF-A 
and PDGF-D were significantly decreased in the heart 3 days after 
TAC, suggesting that dynamic changes in local PDGF expression 
may contribute to activation of PDGFR-β after TAC.
Cardiomyocyte PDGFR-β is not required for normal cardiac development 
or basal adult cardiac function. To further explore the role of PDGFR-β 
signaling in cardiac function, we constructed mice in which PDGFR-β 
was knocked out in cardiomyocytes. This was done by crossing mice 
expressing the Cre recombinase driven by the Nkx2.5 promoter 
(Nkx2.5-Cre mice) (14) with mice in which PDGFR-β was flanked 
by loxP sites (Pdgfrbfl/fl mice) (15). Nkx2.5 is a cardiac-specific tran-
scription factor that exhibits expression at high levels in the heart 
beginning at 9.5 dpc (14). Nkx2.5-Cre:Pdgfrbfl/fl mice (cardiac-specific 
PDGFR-β–knockout mice; PdgfrbNkx-Cre) were born at the expected 
Mendelian frequency (data not shown) and were able to support 
pregnancy. To confirm that the knockout strategy was successful 
and specific, we isolated genomic DNA from the hearts of newborn 
PdgfrbNkx-Cre mice. The presence of the lower PCR band represents the 
Cre-excised allele (Figure 2A), and this was seen in the heart, but not 
in mouse tails or skeletal muscle, while the higher band, the nonex-
cised floxed allele, was markedly diminished in the heart compared 
with other tissues. Furthermore, representative Western blots from 
hearts of 4-week-old mice demonstrated reduced levels of PDGFR-β 
protein in PdgfrbNkx-Cre compared with Pdgfrbfl/fl controls (Figure 2B). 
Analysis of mutant embryos at 15.5 dpc revealed normal cardiac tra-
beculation and no evidence of septal or outflow tract abnormalities 
(data not shown), as observed in conventional knockout models of 
PDGF-B (16) and PDGFR-α (17).
Figure 1
PDGFR-β expression and phosphorylation in cardiomyocytes increase dramatically in response to pressure overload stress. (A) Heart weight/
body weight ratios in 8- to 12-week-old C57BL/6 mice exposed to TAC or sham surgery (Sham). (B) Ratio of the posterior wall thickness of 
hearts from mice exposed to TAC versus sham surgery. Day 0 indicates baseline levels, prior to surgery. (C) Western blot of PDGFR-β levels 
in cardiac lysates harvested after the indicated number of days from animals exposed to TAC or sham surgery. (D) Ratio of PDGFR-β levels 
(normalized for GAPDH) from cardiac lysates from animals exposed to TAC versus sham surgery at the indicated time points (n = 4 samples in 
each group). (E) Immunohistochemical staining for PDGFR-β in cardiac sections from mice exposed to sham surgery (upper panel) or TAC for 
7 days. Arrows indicate cardiomyocytes intensely stained for PDGFR-β. Results are representative of at least 3 separate, independent cardiac 
samples. Scale bars: 50 μm. (F) Western blot probed for phospho-/total levels of PDGFR-β, Akt, and ERK1/2 in hearts of unoperated mice 
(Control) or mice 7 days after TAC or sham surgery. Results are representative of 4 samples in each group. (G) Immunohistochemical staining 
for phospho–PDGFR-β in cardiac sections from mice exposed to sham surgery (upper panel) or TAC for 7 days. Arrows indicate cardiomyocytes 
intensely stained for phospho–PDGFR-β. Scale bars: 50 μm. Asterisks indicate that statistical comparison was between TAC and sham surgery 
at the specified time point. P values were determined by unpaired, 2-tailed Student’s t test.
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When animals were 6 weeks of age, we observed no significant 
difference in cardiac ejection fraction in PdgfrbNkx-Cre compared 
with Pdgfrbfl/fl or Nkx2.5-Cre control mice (Table 1). Notably, we 
did observe a small but significant increase in heart weight/body 
weight ratio in PdgfrbNkx-Cre compared with Pdgfrbfl/fl or Nkx2.5-Cre 
control mice, driven largely by nonsignificant increases in the thick-
ness of the intraventricular septum and posterior walls. In addi-
tion, we observed small, significant increases in lung weight/body 
weight ratios in PdgfrbNkx-Cre mice. Importantly, cardiac ejection frac-
tions, heart weights, and ventricular chamber sizes were normal in 
8-month-old PdgfrbNkx-Cre mice and were not different from those 
of Pdgfrbfl/fl or Nkx2.5-Cre controls (data not shown). Thus, cardio-
myocyte PDGFR-β signaling does not appear to play a key role in 
cardiac development or in basal adult cardiac function.
PDGFR-β cardiac-specific knockout mice develop ventricular dilata-
tion and heart failure in response to pressure overload. To determine 
Figure 2
Cardiac-specific PDGFR-β–knockout mice develop ventricular dilatation and heart failure in response to pressure overload. (A) PCR of genomic 
DNA from tails, skeletal muscle (SM), or hearts (Hrt) from newborn cardiac-specific PDGFR-β–knockout mice (PdgfrbNkx-Cre) mice using primer 
pairs specific for floxed allele (upper band) or deleted allele (lower band). Results are representative of 3 independent experiments. (B) West-
ern blot of cardiac lysates from 4-week-old Nkx2.5-Cre:Pdgfrbfl/fl mice (PdgfrbNkx-Cre) or non–Cre-expressing littermate control (Pdgfrbfl/fl) mice 
probed with an antibody against PDGFR-β. (C) Ratio of right/left (R/L) peak carotid velocity 24 hours after 8- to 12-week-old PdgfrbNkx-Cre or 
Pdgfrbfl/fl mice were exposed to TAC (n = 8 in each group). (D) Cardiac ejection fraction of Pdgfrbfl/fl mice or PdgfrbNkx-Cre mice prior to TAC 
(day 0) or at various time points after TAC, as measured by MRI. (E) Heart weight/body weight ratios of Pdgfrbfl/fl versus PdgfrbNkx-Cre mice 
prior to TAC (day 0) or 14 days after TAC. (F) Representative short-axis MRI still frame images taken at the mid-ventricular level in Pdgfrbfl/fl or 
PdgfrbNkx-Cre mice prior to TAC exposure (left panels) or 14 days after TAC exposure (right panels). (G) Ratio of lung weight/body weight of 
Pdgfrbfl/fl versus PdgfrbNkx-Cre mice prior to TAC or 14 days after TAC. P values were determined by unpaired, 2-tailed Student’s t test. Numbers 
inside the bars indicate the number of animals analyzed.
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whether cardiomyocyte PDGFR-β is a required component of the 
cardiac response to pressure overload, we exposed 8- to 12-week-
old PdgfrbNkx-Cre mice or littermate Pdgfrbfl/fl controls to TAC stress. 
The ratio of right-to-left carotid flow velocities, a surrogate of 
the degree of aortic impedance imposed in our TAC model (18), 
was similar in PdgfrbNkx-Cre mice and Pdgfrbfl/fl controls (Figure 2C). 
Notably, cardiac ejection fractions in PdgfrbNkx-Cre mice were sig-
nificantly decreased compared with those in Pdgfrbfl/fl controls at 
7 days after TAC, with a further decline 14 days after TAC (Fig-
ure 2D). In addition, PdgfrbNkx-Cre mice displayed increased heart 
weight/body weight ratios 14 days after TAC (Figure 2E), indicative 
of enhanced pathologic hypertrophy in PdgfrbNkx-Cre mice after TAC 
stress. Cardiomyocyte cross-sectional area 14 days after TAC was 
significantly increased in PdgfrbNkx-Cre mice compared with Pdgfrbfl/fl 
controls (Supplemental Figure 3), further indicative of a patho-
logic hypertrophy phenotype. Representative short-axis systolic 
and diastolic still frame MRI images (Figure 2F) demonstrated the 
acquired cardiac dysfunction seen in PdgfrbNkx-Cre mice 14 days after 
TAC. Lung weights were significantly increased in PdgfrbNkx-Cre mice 
14 days after TAC (Figure 2G), indicative of pulmonary edema and 
functional heart failure.
Inducible, cardiac-specific PDGFR-β–knockout mice develop severe heart 
failure in response to TAC stress. Our findings in PdgfrbNkx-Cre mice 
suggest that PDGFR-β signaling plays a key role in the cardiac 
response to load stress. However, we could not exclude the possi-
bility that developmental abnormalities and/or expression of Cre 
recombinase in PdgfrbNkx-Cre mice predispose these mice to cardiac 
failure upon exposure to TAC. To specifically determine the role of 
PDGFR-β signaling in the adult cardiac response to load-induced 
stress, we crossed Pdgfrbfl/fl mice with mice expressing the MerCreMer 
transgene driven by the α-MHC promoter (MerCreMer mice), which 
exhibit high cardiac levels of nuclear Cre recombinase activity only 
in the presence of tamoxifen (19). Hearts from α-MHC-MerCreMer:
Pdgfrbfl/fl mice (inducible, cardiac-specific PDGFR-β–knockout 
mice, PdgfrbMerCre) expressed reduced levels of PDGFR-β (Figure 3A) 
compared with non–Cre-expressing, tamoxifen-treated Pdgfrbfl/fl 
controls. We observed no compensatory differences in the expres-
sion of PDGFR-α in the hearts of PdgfrbMerCre mice compared with 
Pdgfrbfl/fl control mice (Supplemental Figure 4). Inducible mutants 
were exposed to a similar degree of TAC stress as either Pdgfrbfl/fl or 
MerCreMer control mice (Figure 3B). Heart weights of tamoxifen-
treated PdgfrbMerCre mice significantly increased 
in response to TAC compared with those of 
tamoxifen-treated Pdgfrbfl/fl or MerCreMer con-
trols (Figure 3C). Cardiomyocyte cross-sec-
tional area 14 days after TAC was significantly 
increased in PdgfrbMerCre mice compared with 
Pdgfrbfl/fl and MerCreMer controls (Supplemen-
tal Figure 5), further indicative of a pathologic 
hypertrophy phenotype in PdgfrbMerCre mice. 
PdgfrbMerCre mice experienced significant 
declines in cardiac ejection fraction 7 days after 
TAC and severe cardiac dysfunction 14 days 
after TAC compared with Pdgfrbfl/fl or MerCre-
Mer controls (Figure 3D). Cardiac dysfunction 
and pathologic hypertrophy in PdgfrbMerCre mice 
was associated with increased ventricular dila-
tation, seen 14 days after TAC in PdgfrbMerCre 
mice (Figure 3E). Representative hearts from 
PdgfrbMerCre mice and Pdgfrbfl/fl controls 14 days 
after TAC demonstrate the observed cardiac dilatation (Figure 3F). 
MRI cine videos demonstrate the load-induced dilated cardiomyop-
athy phenotype in PdgfrbMerCre mice (Supplemental Video 1). Signifi-
cant increases in lung weight, indicative of pulmonary edema, were 
seen in PdgfrbMerCre mice compared with either MerCreMer or Pdgfrbfl/fl 
control mice beginning at 7 days after TAC, and differences were 
even more striking 14 days after TAC (Figure 3G). Expression of 
B-type natriuretic peptide (BNP), a marker of pathologic hypertro-
phy and heart failure (20), was increased in hearts of PdgfrbMerCre 
mice as early as 3 days after exposure to TAC (Figure 3H).
Inducible cardiac-specific PDGFR-β–knockout mice exhibit impaired 
activation of Akt and MAPK pathways in the progression to heart failure. 
To gain insight into the mechanism of load-induced heart failure 
in PdgfrbMerCre mice, we measured changes in the PI3K and MAPK 
pathways, effectors of PDGFR signaling (21) known to mediate the 
compensatory cardiac response to load-induced stress (22). Levels 
of phosphorylation of p38 kinase, whose role in cardiac protec-
tion is ambiguous (23), were significantly decreased in hearts of 
PdgfrbMerCre mice at 7 and 14 days after TAC (Figure 4, A and B). 
Phosphorylation of ERK1/2, previously demonstrated to protect 
the heart in response to load stress (24), was significantly decreased 
at 14 but not 7 days after TAC in PdgfrbMerCre mice (Figure 4, A and 
C). A similar pattern was observed with respect to phosphorylation 
of JNK kinase (Figure 4A). In addition, levels of phosphorylation 
of the protein kinase Akt were significantly reduced in PdgfrbMerCre 
mice compared with Pdgfrbfl/fl controls 14 days after exposure to 
TAC (Figure 4, D and E).
We also observed diminished phosphorylation of both Akt and 
ERK1/2 in the hearts of PdgfrbNkx-Cre mice compared with controls 14 
days after TAC stress (Supplemental Figure 6). Since both Akt and 
ERK1/2 exert cardioprotective effects in part via inhibition of apop-
tosis, we sought to determine whether cardiomyocyte apoptosis 
after TAC was different in PdgfrbMerCre mice compared with Pdgfrbfl/fl 
controls. Consistent with our biochemical findings, the number of 
apoptotic cardiomyocytes was increased in PdgfrbMerCre mice 7 days 
after TAC and continued to rise 14 days after TAC (Figure 4F). Over-
all, these findings suggest that PDGFR-β signaling in the heart may 
participate in modulating the activation of cardioprotective protein 
kinases in the progression of heart failure due to pressure overload.
Angiogenic gene expression profile correlates with defective microvascular 
function in inducible, cardiac-specific PDGFR-β–knockout mice upon expo-
Table 1
Cardiac function and morphometry of 6-week-old cardiac-specific PDGFR-β–knockout 
mice (PdgfrbNkx-Cre) compared with controls (Nkx2.5-Cre and Pdgfrbfl/fl)
	 Nkx2.5-Cre	 Pdgfrbfl/fl	 PdgfrbNkx-Cre	 ANOVA	P	value
BW (g) 21.7 ± 1.6 23.1 ± 1.1 20.9 ± 1.2 0.43
HW (mg) 111.4 ± 11.5 112.6 ± 4.7 118.2 ± 8.5 0.84
HW/BW (mg/g) 5.06 ± 0.19 4.83 ± 0.10 5.62 ± 0.15 0.004
LW (mg) 142.1 ± 13.8 146.0 ± 6.0 158.7 ± 12.9 0.57
LW/BW (mg/g) 6.47 ± 0.20 6.29 ± 0.25 7.53 ± 0.22 0.002
EF (%) 57.7 ± 2.1 58.8 ± 4.3 60.5 ± 2.3 0.81
PWTd (mm) 0.86 ± 0.04 0.92 ± 0.07 1.08 ± 0.09 0.08
IVSTd (mm) 0.68 ± 0.06 0.71 ± 0.05 0.85 ± 0.08 0.46
BW, body weight; HW, heart weight; LW, lung weight; EF, ejection fraction; PWTd, posterior 
wall thickness in diastole; IVSTd, intraventricular septal thickness in diastole. n = 8 animals 
assessed in control groups and n = 7 animals in PdgfrbNkx-Cre group. P values were deter-
mined by ANOVA, and significant differences between mutant and control groups were con-
firmed by Tukey’s test.
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sure to load stress. The majority of the biochemical changes described 
in Figure 4 occurred after the initiation of the heart failure pheno-
type in PdgfrbMerCre mice upon exposure to pressure overload. To 
understand the initiating biological mechanism of heart failure 
in PdgfrbMerCre mice, we focused on identifying biologic changes 
between PdgfrbMerCre mice and Pdgfrbfl/fl controls at time points 
preceding the development of overt heart failure using a broad 
approach, namely microarray gene expression studies. Of the 
genes that were differentially expressed (Supplemental Table 1), 
we focused on a group of genes that exhibited the pattern depict-
ed in Figure 5A — genes expressed in the heart at similar levels in 
PdgfrbMerCre mice and Pdgfrbfl/fl controls prior to TAC but increased 
in Pdgfrbfl/fl controls compared with PdgfrbMerCre mice at early time 
points (3 and 7 days) after TAC. Functional annotation clustering 
of this subset of genes revealed an enrichment of genes that par-
ticipate in multiple facets of angiogenesis (Figure 5B), including 
endothelial cell proliferation (e.g., Agtrl1; ref. 25), endothelial cell 
migration (Angpt1; ref. 26), extracellular matrix remodeling (e.g., 
Mmp2; ref. 27), and proangiogenic transcription factors (e.g., Elk3). 
We thus postulated that PDGFR-β signaling in the cardiomyocyte 
Figure 3
Inducible, cardiac-specific PDGFR-β–knockout mice develop severe heart failure in response to pressure overload. (A) Expression of PDGFR-β 
in hearts from α-MHC-MerCreMer:Pdgfrbfl/fl mice (inducible, cardiac-specific PDGFR-β–knockout mice, PdgfrbMerCre) or Pdgfrbfl/fl controls har-
vested 7 days after exposure to tamoxifen. Results are representative of 4 independent hearts assessed from each group. (B) Ratio of right/left 
peak carotid velocity 24 hours after 8- to 12-week-old PdgfrbMerCre, MerCreMer, or Pdgfrbfl/fl mice were exposed to TAC. All groups of mice 
were treated with tamoxifen in an identical manner prior to baseline analysis and exposure to TAC stress (see Methods). (C) Heart weight/body 
weight ratios in 8- to 12-week-old PdgfrbMerCre, MerCreMer, or Pdgfrbfl/fl mice after TAC. (D) Cardiac ejection fraction of PdgfrbMerCre, MerCre-
Mer, or Pdgfrbfl/fl mice prior to TAC or at time points after TAC, as measured by MRI. (E) LV end diastolic volume of PdgfrbMerCre, MerCreMer, or 
Pdgfrbfl/fl mice 14 days after TAC. (F) Representative hearts from Pdgfrbfl/fl or PdgfrbMerCre mice 14 days after TAC. (G) Expression levels of BNP 
assessed from mRNA from hearts of Pdgfrbfl/fl or PdgfrbMerCre mice prior to TAC or at time points after TAC (n = 4 samples per group at each 
time point). (H) Ratio of lung weight/body weight of PdgfrbMerCre, MerCreMer, or Pdgfrbfl/fl mice at baseline or at time points after TAC. P values 
were determined by ANOVA, and significant differences between PdgfrbMerCre and control (MerCreMer and Pdgfrbfl/fl) mice were confirmed with 
Tukey’s test. Numbers inside the bars indicate the number of animals analyzed.
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regulates cardiac angiogenesis in response to stress. This hypoth-
esis correlates with reports indicating that the cardiomyocyte itself 
is a paracrine cell functioning to enhance blood vessel growth dur-
ing conditions of increased substrate demand (28–30).
To test this hypothesis, we measured coronary flow reserve 
(CFR), which provides a robust assessment of coronary micro-
vascular function in mice (31) and humans (32). Representative 
tracings (Figure 5C) of coronary flow in response to vasodilator 
stimulus (2.5% inhaled isoflurane; ref. 33) demonstrate reduced 
hyperemic coronary flow in PdgfrbMerCre mice at baseline and after 
TAC. Quantification of CFR demonstrated a significant reduction 
at baseline in PdgfrbMerCre mice compared with either MerCreMer 
or Pdgfrbfl/fl controls (Figure 5D). By 7 days after TAC, PdgfrbMerCre 
mice had minimal augmentation of coronary flow in response to 
Figure 4
Inducible, cardiac-specific PDGFR-β–knockout mice exhibit impaired activation of Akt and MAPK pathways in the progression to heart failure. 
Representative Western blots from cardiac lysates of PdgfrbMerCre mice (inducible, cardiac-specific PDGFR-β–knockout mice) or Pdgfrbfl/fl con-
trols harvested prior to TAC or at indicated time points after TAC probed for (A) phospho-/total p38, phospho-/total ERK1/2, and phospho/total 
JNK or (D) phospho-/total Akt. (B, C, and E) Quantification by densitometry (n = 4 independent samples per group per time point) of ratios of 
(B) phospho-/total p38, (C) phospho-/total ERK1/2, or (E) phospho-/total Akt. (F) Number of apoptotic cells per 100,000 myocytes from hearts 
of PdgfrbMerCre mice or Pdgfrbfl/fl controls assessed at 7 or 14 days after TAC. Data represent results from 2 spatially separated samples from 3 
separate animals from each group at each time point. P values were determined by unpaired, 2-tailed Student’s t test.
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Figure 5
Angiogenic gene expression profile correlates with defective microvascular function in inducible, cardiac-specific PDGFR-β–knockout mice 
upon exposure to load stress. (A) Pattern of change of genes of interest over time prior to and after TAC (red, PdgfrbMerCre; blue, Pdgfrbfl/fl). (B) 
Change of expression from baseline (ratio of PdgfrbMerCre to Pdgfrbfl/fl) of genes associated with multiple aspects of angiogenesis (n = 4 samples 
in each group at each time point). (C) Representative ultrasound tracings of maximal coronary flow after hyperemic stimulus prior to TAC or 
14 days after TAC in control Pdgfrbfl/fl or PdgfrbMerCre mice. (D) Quantification of CFR in Pdgfrbfl/fl, MerCreMer, or PdgfrbMerCre mice (n = 7 in each 
group at each time point). (E) Quantification of cardiac perfusion as assessed by myocardial contrast uptake (see Methods) from 0° (anterior 
wall of the left ventricle) to 90° (lateral wall of left ventricle) 14 days after TAC in PdgfrbMerCre or Pdgfrbfl/fl control mice (n = 3 PdgfrbMerCre mice, 
n = 4 Pdgfrbfl/fl control mice). P values were determined by ANOVA, and significant differences between PdgfrbMerCre and control (Pdgfrbfl/fl and 
MerCreMer) mice were confirmed with Tukey’s test.
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vasodilator stimulus (CFR = 1), suggestive of a severe coronary 
microvascular defect. To determine whether PdgfrbMerCre mice had a 
global decline in myocardial perfusion in response to TAC, we used 
a microbubble perfusion method, producing a contrast-enhanced 
ultrasound signal in the myocardium that is directly proportional 
to perfusion (34). Using this technique throughout all assessable 
portions of the heart (the anterior and lateral segments of the left 
ventricle), we observed a reduction in myocardial perfusion in Pdg-
frbMerCre mice compared with Pdgfrbfl/fl controls (Figure 5E). Overall 
myocardial perfusion was reduced by 24.6% in inducible-mutant 
mice compared with controls 14 days after TAC (n = 3 PdgfrbMerCre 
mice, n = 4 Pdgfrbfl/fl mice, P = 0.01).
Impaired angiogenesis and evidence of ischemic injury in the hearts of 
inducible, cardiac-specific PDGFR-β–knockout mice upon exposure to 
load stress. Recent work demonstrates that angiogenesis is a cru-
cial adaptive mechanism accompanying cardiac hypertrophy and 
manifesting as an increased number of coronary microvessels per 
cardiomyocyte (29). To determine whether coronary angiogenesis 
in response to pressure overload was impaired in PdgfrbMerCre mice, 
we quantified coronary microvessels at baseline or after TAC expo-
sure. The number of CD31 microvessels per myocyte at baseline 
was not different in the hearts of PdgfrbMerCre mice compared with 
Pdgfrbfl/fl controls (Figure 6A). In contrast, while Pdgfrbfl/fl and Mer-
CreMer control mice had a rise in coronary microvessels per car-
diomyocyte in response to TAC consistent with previous findings 
(29), this increase was significantly blunted in PdgfrbMerCre mice at 
7 and 14 days after TAC. Representative photomicrographs from 
hearts 14 days after TAC demonstrate the reduction in microvas-
cular density in hearts of PdgfrbMerCre mice compared with MerCre-
Mer or Pdgfrbfl/fl controls (Figure 6B).
Histologically, hearts from PdgfrbMerCre mice demonstrated a 
significant increase in fibrosis (Figure 6C) distributed through-
out the subendocardium, the portion of the heart most suscep-
tible to ischemic injury. To determine whether the reduction in 
angiogenesis resulted in functional myocardial ischemia, we used 
2-nitroimidazole, an immunochemical marker for cardiac hypox-
ia (29). We observed a significant increase in myocardial hypoxia 
in PdgfrbMerCre mice 7 days after TAC (Figure 6E) and a more dra-
Figure 6
Impaired angiogenesis and evidence of ischemic injury in the hearts of inducible, cardiac-specific PDGFR-β–knockout mice upon exposure to 
load stress. (A) Microvessel number per cardiomyocyte in Pdgfrbfl/fl, MerCreMer, or PdgfrbMerCre mice at baseline (day 0) or at time points after 
TAC. (B) Representative photomicrographs of cardiac sections stained with an anti-CD31 antibody from Pdgfrbfl/fl, MerCreMer, or PdgfrbMerCre 
hearts 14 days after TAC. Scale bars: 100 μm. (C) Low-power (original magnification, ×15) photomicrographs of representative Masson’s 
trichrome–stained cardiac sections from Pdgfrbfl/fl or PdgfrbMerCre mice 14 days after TAC reveal diffuse, subendocardial fibrosis in hearts of 
PdgfrbMerCre exposed to load stress (upper panels). High-power photomicrographs of portion of sections in C indicated by boxed region (lower 
panels). Scale bars: 50 μm. (D) Representative photomicrographs of cardiac sections from PdgfrbMerCre or Pdgfrbfl/fl control mice assessed for 
hypoxia (see Methods) 14 days after TAC. Scale bars: 50 μm. (E) Quantification of hypoxic area in hearts of PdgfrbMerCre or Pdgfrbfl/fl control mice 
after TAC. Data represent mean of multiple fields from independent sections from 3 separate mice in each group at each time point.
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matic increase in hypoxia in the hearts of PdgfrbMerCre mice 14 days 
after TAC, visually demonstrated in Figure 6D. Biochemically, we 
observed increased levels of the transcription factor HIF-1α, whose 
expression increases in the ischemic heart (35), 7 days after TAC in 
PdgfrbMerCre mice compared with Pdgfrbfl/fl controls (Supplemental 
Figure 7), along with increased levels of the HIF-1α–dependent fac-
tor VEGF-A. However, 14 days after TAC, both HIF-1α and VEGF-A 
levels were significantly reduced in the hearts of PdgfrbMerCre 
mice despite profound tissue hypoxia. Taken together, our find-
ings demonstrate that loss of cardiomyocyte PDGFR-β signaling 
results in a functional and structural defect in coronary microvas-
cular flow accompanied by evidence of global myocardial ischemia 
in response to pressure overload–induced stress.
Cardiomyocyte PDGFR-β is an essential regulator of the paracrine angio-
genic capacity of cardiomyocytes. Our in vivo observations demon-
strate that loss of cardiomyocyte PDGFR-β results in load-induced 
Figure 7
Cardiomyocyte PDGFR-β is an upstream regulator of the paracrine angiogenic capacity of cardiomyocytes. (A) FACS analysis of cardiomyocytes 
from Pdgfrbfl/fl mice stained with anti–sarcomeric myosin antibody. (B) Genomic PCR of cardiomyocytes from Pdgfrbfl/fl mice before infection 
(Ctrl) or after infection with Ad-GFP or Ad-Cre using primers for floxed allele (upper band) or deleted allele (lower band). (C) Quantitative RT-PCR 
for PDGFR-β expression (normalized to GAPDH) using RNA derived from cardiomyocytes from Pdgfrbfl/fl mice before infection (Control) or after 
infection with Ad-GFP or Ad-Cre. (D) Relative tube-forming capacity of conditioned media from cardiomyocytes from Pdgfrbfl/fl mice before infec-
tion (Control) or after infection with Ad-GFP or Ad-Cre with or without exogenous PDGF-BB. (E) Relative tube-forming capacity of conditioned 
media from cardiomyocytes from Pdgfrbfl/fl mice before infection or after infection with Ad-GFP or Ad-Cre under normoxic or hypoxic conditions. 
(F) Relative tube-forming capacity of conditioned media from cardiomyocytes from wild-type mice before or after infection with Ad-GFP or Ad-Cre 
and subsequent exposure to hypoxia. (G) Relative endothelial cell proliferation in conditioned media from wild-type and Pdgfrbfl/fl cardiomyocytes 
before or after infection with Ad-GFP or Ad-Cre and exposed to hypoxia. *P < 0.001. (H) Ratio of reduction in expression (quantitative RT-PCR, 
normalized to GAPDH) of proangiogenic genes in cardiomyocytes from Pdgfrbfl/fl mice infected with Ad-Cre or Ad-GFP and exposed to hypoxia. 
*P < 0.05. Data were derived from 4 independent experiments.
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cardiac dysfunction associated with impairment in cardiac angio-
genesis. Based upon our gene expression data (Figure 5, A and 
B), we hypothesized that PDGFR-β is a regulator of the paracrine 
angiogenic capacity, or angiogenic potential, of cardiomyocytes. 
To test this hypothesis, we isolated a highly purified population of 
neonatal cardiomyocytes from Pdgfrbfl/fl mice (Figure 7A). In vitro 
infection of these cardiomyocytes with Ad-Cre, but not with Ad-
GFP, resulted in deletion of the floxed allele, detectable by PCR 
of genomic DNA (Figure 7B). Cre-mediated deletion of the floxed 
PDGFR-β allele from isolated cardiomyocytes resulted in a marked 
decrease in mRNA encoding PDGFR-β (Figure 7C).
Using this primary cardiomyocyte model, we first explored the 
ability of PDGF stimulation to enhance the ability of cardiomyo-
cytes to support angiogenesis. In experiments in which cardio-
myocytes from Pdgfrbfl/fl mice were used, conditioned media from 
control, noninfected cardiomyocytes, Ad-GFP–infected cardiomy-
ocytes, or Ad-Cre cardiomyocytes was harvested before and after 
treatment with PDGF-BB or vehicle control. Conditioned media 
from control or Ad-GFP cardiomyocytes demonstrated a marked 
increase in the capacity to promote endothelial tube formation (a 
surrogate assay to assess the angiogenic capacity of cardiomyo-
cytes) after treatment with PDGF-BB (Figure 7D), an effect not 
directly attributable to PDGF-BB (see Media, white bars). In con-
trast, the angiogenic capacity of conditioned media from cardio-
myocytes in which PDGFR-β was deleted by Ad-Cre infection was 
not enhanced by PDGF-BB treatment. These findings demonstrate 
that PDGF-BB potently enhances the paracrine angiogenic capac-
ity of cardiomyocytes in a PDGFR-β–dependent manner.
To determine whether PDGFR-β is a required component of 
the angiogenic potential of cardiomyocytes under conditions of 
physiologic stress, we exposed control, Ad-GFP–infected, or Ad-
Cre–infected neonatal cardiomyocytes from Pdgfrbfl/fl mice to 
hypoxia, then harvested the conditioned media from these myo-
cytes and tested its ability to support endothelial tube formation. 
Hypoxia significantly increased the capacity of conditioned media 
from control and Ad-GFP cardiomyocytes to support tube forma-
tion (Figure 7E). In contrast, we saw a reduction in the angiogenic 
capacity of conditioned media from Ad-Cre–infected, PDGFR-β– 
deleted cardiomyocytes upon exposure to hypoxic stress. To 
determine whether Ad-Cre infection had a direct toxic effect on 
the angiogenic capacity of cardiomyocytes, we infected control 
neonatal cardiomyocytes (not bearing the PDGFR-β floxed allele) 
with Ad-Cre or Ad-GFP and exposed these myocytes to hypoxia. 
As shown in Figure 7F, Ad-Cre infection had no effect on the 
paracrine ability of cardiomyocytes to support endothelial tube 
formation in response to hypoxia. As an independent measure of 
the PDGFR-β–dependent paracrine angiogenic capacity of cardio-
myocytes, we found that conditioned media from Ad-Cre–infected 
cardiomyocytes from Pdgfrbfl/fl mice exposed to hypoxia had an 
impairment in the ability to support in vitro endothelial cell prolif-
eration compared with Ad-GFP or control cardiomyocytes (Figure 
7G). Experiments using wild-type cardiomyocytes demonstrated 
that this impairment in promoting endothelial cell proliferation is 
not attributable to Ad-Cre infection (Figure 7G). Furthermore, we 
identified a series of factors known to enhance in vivo angiogen-
esis that demonstrated a trend toward reduced expression in Ad-
Cre–infected, PDGFR-β–deficient cardiomyocytes compared with 
control, Ad-GFP–infected cardiomyocytes after both cell models 
were exposed to hypoxia in vitro (Figure 7H), including statisti-
cally significant reductions in expression of Cxcl1, Cxcl2, and Fgf1. 
Thus, our findings demonstrate that PDGFR-β is an essential reg-
ulator of the angiogenic capacity of cardiomyocytes in response to 
hypoxic stress, in part through regulation of a program of expres-
sion of angiogenic factors. These findings are consistent with and 
provide a direct mechanistic basis for the cardiac dysfunction and 
impairment of load stress–induced angiogenesis observed in car-
diac-specific PDGFR-β–knockout mice.
Discussion
We show here that PDGFR-β is an indispensable component of the 
cardiac response to pressure overload–induced stress. The robustness 
of our findings is reflected in the similarity of phenotype in 2 inde-
pendent but overlapping knockout systems. Mechanistically, our 
findings suggest that PDGFR-β signaling is an important upstream 
regulator of the angiogenic potential of the cardiomyocyte in 
response to stress. The notion that PDGFR signaling regulates pro-
angiogenic pathways has precedent in other systems. For example, 
PDGFR signaling in tumor-associated stromal cells exerts a proan-
giogenic effect in the tumor microenvironment (36). Furthermore, a 
recent report revealed that knockout of PDGFR-β in the epicardium 
inhibits normal development of epicardial coronary arteries (37).
PDGFR-β signaling in the cardiomyocyte may regulate angio-
genesis in the heart in response to load-induced stress through 
several different mechanisms. Recent work has demonstrated that 
activation of the PI3K and MAPK pathways enhance the angiogen-
ic capacity of cardiomyocytes via a HIF-1α/VEGF-A–dependent 
mechanism (30). Intriguingly, we observed an increase in levels of 
phosphorylated Akt and a decrease in levels of phosphorylated p38 
in the hearts of PdgfrbMerCre mice prior to TAC compared with levels 
in hearts of Pdgfrbfl/fl mice (Figure 4), although these changes did not 
achieve statistical significance when quantified by densitometry. 
Furthermore, we observed significantly decreased phosphoryla-
tion of Akt, p38, and ERK1/2 together with significantly decreased 
expression of HIF-1α and VEGF-A in PdgfrbMerCre mice 14 days after 
exposure to TAC stress. However, at earlier time points after TAC 
(day 7), expression of both HIF-1α and VEGF-A were increased in 
PdgfrbMerCre mice exposed to TAC compared with Pdgfrbfl/fl control 
mice. By this time point, PdgfrbMerCre mice already exhibited car-
diac dysfunction along with markedly reduced numbers of blood 
vessels per cardiomyocyte and functional hypoxia. These observa-
tions suggest that the PDGFR-β–dependent angiogenic capacity 
of cardiomyocytes is independent of HIF-1α/VEGF-A expression. 
Elucidation of the signaling pathways downstream of PDGFR-β 
that are essential regulators of the PDGFR-β–dependent angiogen-
ic capacity of cardiomyocytes is a goal of our future studies, as is 
the determination of the precise identity of paracrine factors that 
mediate the PDGFR-β–dependent paracrine angiogenic capacity of 
cardiomyocytes. Importantly, cardiomyocyte PDGFR-β signaling 
may regulate aspects of the cardiac response to pressure overload 
other than angiogenesis (e.g., substrate utilization) that substan-
tially contribute to heart failure in cardiac-specific PDGFR-β– 
knockout mice, which we will explore in future studies.
Our findings suggest that therapeutics that augment cardio-
myocyte PDGFR signaling in the heart may be a novel strategy 
for the treatment of cardiac disease in which defective angio-
genesis is a contributor to disease pathogenesis. Consistent 
with this hypothesis are prior studies that demonstrate that 
administration of PDGF-BB prevents adverse remodeling after 
experimental myocardial infarction (38, 39). More generally, 
our findings support the general notion that targeting cardiac 
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angiogenesis through the PDGF/PDGFR system or via other 
means may be an effective approach to prevent the progression 
of multiple forms of heart failure (40), including “nonischemic” 
cardiomyopathies, in which functional and structural microvas-
cular abnormalities are well described (41).
Our studies were inspired by observations of cardiac toxicity in 
cancer patients treated with PDGFR inhibitors. Our results pro-
vide a mechanistic rationale to aggressively treat hypertension and 
thus minimize vascular stress as a strategy to prevent heart failure 
due to anticancer PDGFR inhibitors. Based on our findings, we 
also speculate that patients with preexisting coronary disease at 
the macro- or microvascular level may be at increased risk for car-
diomyopathy and heart failure associated with these drugs. Con-
firmation of such findings could provide the basis for a risk strati-
fication tool in cancer patients being considered for treatment 
with PDGFR inhibitors and could be used to develop strategies to 
prevent adverse cardiac effects of PDGFR inhibitors.
It is important to note that targets other than PDGFR may be 
involved in cardiotoxicity due to anticancer PDGFR inhibitors. 
Both sunitinib and sorafenib can exert substantial off-target 
effects on other kinases (42), and these can be independent or 
additive to their effects on cardiomyocyte PDGFR signaling that 
result in clinical heart failure. Furthermore, cardiotoxicity due to 
imatinib has been demonstrated to involve Abl kinase (11, 43), 
while the role of PDGFR signaling in cardiotoxicity due to ima-
tinib is unclear (44). Fundamentally, it is of critical importance to 
determine the contribution of the inhibitory effects on PDGFR to 
the clinical cardiac toxicity observed with RTK inhibitors whose 
targets include PDGFR. Such information will be useful to achieve 
the goal of designing highly efficacious, novel anticancer agents 
with minimal cardiotoxicity.
Finally, our studies highlight the opportunities for discovery 
that can be capitalized upon based upon cardiac toxicity of novel, 
targeted anticancer agents. Such toxicities may reveal biological 
pathways whose role in the regulation of cardiovascular physiol-
ogy were previously unknown, and detailed exploration of such 
pathways may be useful for developing new, effective treatments 
for multiple forms of human heart failure.
Methods
Developmental, cardiac-specific PDGFR-β–knockout mice. Mice expressing Cre 
recombinase driven by the Nkx2.5 promoter (C57BL/6 background) were 
crossed with Pdgfrbfl/fl mice (129 background) to create Nkx2.5-Cre:Pdgfrbfl/fl 
(PdgfrbNkx-Cre) mice or littermate control, non–Cre-expressing Pdgfrbfl/fl mice 
(mixed C57BL/6 × 129 background). To study the effects of the Nkx2.5-Cre 
transgene on basal cardiac function in an identical genetic background, we 
crossed mice expressing Cre recombinase driven by the Nkx2.5 promoter 
(C57BL/6 background) with wild-type 129 mice to generate Nkx2.5-Cre 
mice in a mixed C57BL/6 × 129 background. Nkx2.5-Cre mice were pro-
vided by R.J. Schwartz (Institute of Biosciences and Technology, Hous-
ton, Texas, USA). Pdgfrbfl/fl mice were provided by P. Soriano (Mount Sinai 
School of Medicine, New York, New York, USA).
Inducible, cardiac-specific Pdgfrb-knockout mice. To create inducible, cardiac-
specific PDGFR-β–knockout mice, we crossed heterozygous α-MHC-Mer-
CreMer mice (C57BL/6 background) with Pdgfrbfl/fl mice (129 background), 
resulting in Pdgfrbfl/fl mice and α-MHC-MerCreMer:Pdgfrbfl/fl (PdgfrbMerCre) 
mice in a mixed C57BL/6 × 129 background. To study any possible con-
tribution of the α-MHC-MerCreMer transgene, we used heterozygous 
α-MHC-MerCreMer mice in a similar, mixed C57BL/6 × 129 background. All 
groups were treated with 4-hydroxytamoxifen beginning at age 6–8 weeks. 
4-Hydroxytamoxifen was administered intraperitoneally at a dosage of 20 
mg/kg/d for a total of 5 days. Mice were given 7–10 days of rest after the 
last dosage of 4-hydroxytamoxifen prior to functional characterization or 
to exposure to pressure overload–induced stress induced by TAC.
TAC. The University of Texas MD Anderson Cancer Center Institutional 
Animal Care and Use Committee approved all animal protocols used in this 
study. Eight- to 12-week-old male mice were used for functional experiments. 
TAC surgeries were performed based on previously described protocols (45). 
The sham procedure was similar, except that the aorta was not ligated.
Ultrasound measurement of aortic, carotid, and coronary flows. Carotid veloci-
ties were measured 24 hours, 7 days, and 14 days after TAC using a 20-Mhz 
ultrasound probe connected to a signal processing unit (Indus Instruments) 
using our previously published protocol (46). CFR was measured as previous-
ly described (33). Briefly, the ultrasound probe tip was placed at the left side 
of the chest of the anesthetized animal and stabilized using a micromanipu-
lator (model MM3-3, World Precision Instruments). Peak coronary velocities 
were identified, and the probe was fixed in position. Baseline coronary flow 
was measured at 1.0% isoflurane. As a coronary vasodilator stimulus, the 
inhaled isoflurane concentration was increased to 2.5%. The coronary vaso-
dilatory properties of isoflurane in general are well described (47), and we 
have previously validated its use in the measurement of CFR in conjunction 
with a noninvasive ultrasound technique (33, 48). Ratios of peak velocities at 
low- (1%) and high-dose (2.5%) isoflurane were reported as CFR.
In vivo myocardial perfusion studies. For myocardial perfusion studies, short- 
and long-axis echocardiographic images were obtained using the Vevo 770 
machine (Visual Sonics). Baseline short-axis images were obtained, followed 
by injection of a 50-μl bolus containing 1.2 × 107 DEPO Micromarker micro-
bubbles (Visual Sonics) via tail vein. After 12–15 minutes of contrast agent 
bolus injection, short-axis images were again captured without moving the 
probe. Global perfusion was only assessable in the anterior and lateral por-
tions of the left ventricle, due to shadowing cast on the septum and poste-
rior aspect of the heart, rendering this data uninterpretable. Quantification 
of overall perfusion was performed by integrating contrast values obtained 
from 9 separate measurements from each of at least 3 mice in each group.
Cardiac MRI. Cardiac function in experimental mice was measured by 
magnetic resonance (MR) scanning using a retrospectively gated imaging 
method (49). MR scanning experiments were performed using a Bruker 7T 
MR scanner (BioSpin MRI). Mice were anesthetized using 1%–3% isoflurane 
in oxygen, and 0.5%–1.5% isoflurane was delivered to maintain anesthesia. 
During MR scanning, heart rates and respiratory rates were 350–500 beats/
minute and 25–40/minute, respectively. Each MR scan included a scout; sin-
gle-slice sagittal and coronal long-axis cine images of the heart; and a series 
of axial short-axis cine acquisitions. Sagittal and coronal images were used 
to establish the cardiac axis and to identify the apex for prescribing short-
axis cine slices. Short-axis cine images were used to quantify LV end-diastolic 
and -systolic volumes. LV volumes, anterior and posterior wall thickness, and 
LV internal diameter at different phases of the cardiac cycle were measured 
using ParaVision software (Bruker BioSpin). The total cross-sectional area in 
the 1-mm-thick short-axis slices (typically 6–8 slices) from apex to base was 
integrated to calculate ventricular volumes and ejection fractions.
Tissue preparation. We used a previously published method adopted to 
arrest hearts of inducible mutant mice or controls in diastole and fix them 
in 10% formalin (50). Five-micrometer sections of formalin-fixed, paraf-
fin-embedded tissue were used for TUNEL assay, H&E staining, Masson’s 
trichrome staining, and immunohistochemistry.
Myocyte cross-sectional area. Horizontal short-axis cut hearts were fixed in 
10% buffered formalin solution for 24 hours. Paraffin-embedded hearts 
were sectioned at 5-mM thickness. All the sections were stained accord-
ing to previously standard methods. Briefly, sections were deparaffinized, 
rehydrated, and then incubated for 1 hour with TRITC-labeled lectin 
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(100 μg/ml; Sigma-Aldrich). Multiple ×400 magnified pictures were cap-
tured using a fluorescence microscope (Olympus BX41) from epicardial 
and endocardial areas of the left ventricle. Myocytes (40–60/heart) that 
showed round capillaries and clear membrane staining were included in 
the analysis. The Scion Image (Scion Corp.) program was used to calcu-
late cross-sectional area.
Measurement of microvascular density. We used an antibody directed against 
CD31 (BD Biosciences) to stain cardiac microvessels. Detection, staining, 
and counterstaining with hematoxylin was performed using standard 
methods. For quantification of microvessels, at least 3 random fields 
(×400) from each of 2 independent sections for each heart assessed were 
analyzed. To normalize microvessel density to the number of cardiomyo-
cytes present, the same images used to quantify microvessel number were 
used to count cardiomyocyte nuclei, which were identified based upon 
their morphologic appearance made visible by counterstaining.
TUNEL assay. TUNEL staining was performed on formalin-fixed, paraffin-
embedded tissue using the In Situ Cell Death Detection Kit (Roche Applied 
Science). Sections were counterstained with DAPI, and apoptotic cells per 105 
cardiomyocytes were quantified using previously described methods (51).
Tissue hypoxia measurement. To analyze tissue hypoxia 7 and 14 days after 
TAC, we treated all mice intraperitoneally with 60 mg/kg pimonidazole 
hydrochloride (Hypoxyprobe, Natural Pharmacia International) 3 hours 
prior to sacrifice. Immunodetection of Hypoxyprobe binding, indicative of 
tissue hypoxia, was performed using a previously described method (52). 
For quantification of cardiac hypoxic area, at least 6 high-magnification 
(×400) randomly chosen fields from the left ventricle were selected for 
quantification of immunopositive cells, and the average number of posi-
tive staining cells per field was used as an index of tissue hypoxia. Quanti-
fication of hypoxic area in hearts of inducible mutant or control mice after 
TAC was performed by an investigator blinded to the sample identifica-
tion, using NIH ImageJ software (http://rsbweb.nih.gov/ij/) incorporat-
ing standard, grid-based quantitative morphometric techniques (53). For 
determination of statistical significance between groups at each day, we fit 
a mixed-effects linear model, with genotype as the fixed effect and animal 
as the random effect. We used an F-test to determine the significance of 
differences between genotypes.
Quantitative densitometry. Primary antibodies from Cell Signaling Tech-
nology were directed at the following antigens: Akt, phospho-Akt (Ser473), 
ERK1/2, phospho-ERK1/2 (Thr202/Tyr204), PDGFR-β, JNK, phospho-
JNK (Thr183/Tyr185), p38, and phospho-p38 (Thr180/Tyr182). Primary 
antibodies obtained from Santa Cruz Biotechnology Inc. were directed at 
the following antigens: VEGF-A, GAPDH, GATA4, and phospho–PDGFR-β 
(Tyr 1021). Anti–HIF-1α antibody was obtained from Novus Biologicals. 
Protein bands were quantified via densitometry using Fluorchem 8900 
imaging software (Alpha Innotech).
RNA isolation for quantitative RT-PCR and gene expression microarrays. Total 
RNA was isolated from heart tissues using TRIzol (Invitrogen) reagent 
using the manufacturer’s recommended protocol. RNA integrity was 
confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies), 
with samples run against an RNA ladder of specified molecular weights 
(Eukaryote Total RNA Nano Series II, Agilent Technologies).
Gene expression microarrays. Mouse genome 430 2.0 array gene chips were 
purchased from Affymetrix and probed with RNA according to the man-
ufacturer’s recommended protocol using a double in vitro transcription 
method, and data were processed for analysis as previously described (54).
Genotyping by PCR. Genomic DNA was extracted from mouse tails with 
the RedExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich). Primers were as 
follows: Nkx2.5-Cre forward, 5′-GGCGTTTTCTGAGCATACCT-3′, and 
Nkx2.5-Cre reverse, 5′-CTACACCAGAGACGGAAATCCA-3′; internal 
control forward, 5′-CTAGGCCACAATTGAAAGATCT-3′, and internal 
control reverse, 5′-GTAGGTGGAAATTCTAGCATCATCC-3′; MerCre-
Mer forward, 5′-ATACCGGAGATCATGCAAGC-3′, and MerCreMer 
reverse, 5′-AGGTGGACCTGATCATGGGAG-3′; internal control for-
ward, 5′-CTAGGCCACAATTGAAAGATCT-3′, and internal control 
reverse, 5′-GTAGGTGGAAATTCTAGCATCATCC-3′. To check for the 
Pdgfrb floxed/deleted allele, the forward primer was 5′-GGAAAAGCAG-
GTTTGTGC-3′, the floxed reverse primer was 5′-TACCAGGAAGGCTT-
GGGAAG-3′, and the deleted allele reverse primer was 5′-CCAGT-
TAGTCCACCTATGTTG-3′.
Neonatal murine cardiomyocyte isolation, adenoviral infection, and hypoxia. Neo-
natal mouse cardiomyocytes were isolated using a commercially available 
kit from Cellutron (55). Briefly, hearts from 2- to 3-day-old wild-type or 
Pdgfrbfl/fl mice were removed and incubated with digestion medium and then 
centrifuged to collect the dissociated cells from the medium. Cell cultures 
were at least 95% pure of cardiomyocytes as determined by flow cytometry 
after immunostaining of cardiac myosin, a marker of cardiomyocytes. Cells 
were infected with 25 MOI of adenoviral CMV-GFP or adenoviral CMV-
CreGFP (gifts of M.D. Schneider, Imperial College, London, United King-
dom) in growth medium for 48 hours, and then cells were incubated at 
37°C with serum-free DMEM F12 (Invitrogen) for 16–24 hours. After 16 
hours exposure of cells to hypoxia (1% O2, 5% CO2, at 37°C) or normoxia 
(21% O2, 5% CO2, at 37°C), condition medium was collected and stored at 
–80°C. Cells were collected in TRIzol reagent for RNA isolation.
Endothelial cell proliferation and tube formation assays. HUVECs were cul-
tured in growth medium (5,000 cells/well of 96-well plate). After 3 hours 
of incubation, growth medium was replaced with condition medium and 
then incubated for 24 hours. Cells were counted using a Coulter Z series 
device. The in vitro angiogenesis assay kit was purchased from Millipore, 
and the assay method was adapted from previous reports (56). Briefly, 
HUVECs were cultured using endothelial growth medium for 12 hours. 
HUVECs (5 × 103/well of a 96-well plate) were resuspended in 150 μl condi-
tion medium (from 16-hour hypoxia or normoxia) supplemented with 2% 
heat-inactivated FBS. Resuspended cells were seeded onto the surface of 
the ECM-coated wells. After 4–8 hours incubation, 3–5 random view fields 
(×40 magnified) were pictured for each well. Tube length was calculated 
using ImageJ software.
Statistics. In all figures and within the text, data are presented as 
mean ± SEM. We tested the data for normality using the Kolmogorov-
Smirnov test. To assess statistical significance between groups, we used 
the unpaired 2-tailed Student’s t test or, when appropriate, we used the 
nonparametric, 2-sided Wilcoxon rank-sum test. A P value less than 0.05 
was considered statistically significant. Changes between multiple groups 
were calculated using ANOVA, and Tukey’s test was then used to test for 
significant changes between individual groups.
For identification of genes of interest between mutant and control mice 
over time after TAC using gene expression microarrays, we fit an ANOVA 
model that accounts for differences due to genotype differences between 
the 3 time points (day 0, 3, or 7), as well as potential interactions between 
genotype and day. We used a false discovery rate of 1% to identify genes of 
interest using this method. To better understand the behavior of the genes 
found to be differentially expressed by the model (with interaction between 
treatment and day), we used clustering to group these genes into sets that 
exhibited similar expression patterns. Gene annotation enrichment analy-
sis of clustered genes was performed using the NIH DAVID annotation 
tool (http://david.abcc.ncifcrf.gov).
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